Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
OTCMKTS:GTBP

GT Biopharma - GTBP Stock Forecast, Price & News

$1.70
-0.13 (-7.10%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.62
$1.83
50-Day Range
$1.53
$2.20
52-Week Range
$1.46
$4.59
Volume
40,038 shs
Average Volume
35,555 shs
Market Capitalization
$55.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

GT Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
576.5% Upside
$11.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

GTBP stock logo

About GT Biopharma (OTCMKTS:GTBP) Stock

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Stock News Headlines

GTBP GT Biopharma, Inc.
GT Biopharma Poster Presentation and Mini Oral...
See More Headlines
Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Company Calendar

Last Earnings
10/31/2022
Today
11/29/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GTBP
Previous Symbol
OTCMKTS:OXISD
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+576.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-58,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.72 per share

Miscellaneous

Free Float
30,572,000
Market Cap
$55.35 million
Optionable
Not Optionable
Beta
0.73

Key Executives

  • Mr. Michael Martin Breen (Age 59)
    Interim CEO & Exec. Chairman
    Comp: $378.02k
  • Dr. Gregory I. Berk M.D. (Age 64)
    Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board
    Comp: $526.39k
  • Dr. Gavin S. Choy MBA
    PharmD, Chief Clinical Devel. Officer
  • Mr. Manu Ohri (Age 67)
    Chief Financial Officer
  • Dr. Jeffrey S. Miller M.D.
    Consulting Chief Scientific Officer & Scientific Advisor
  • Ms. Stacy Herb M.B.A.
    M.P.H., Sr. VP of Portfolio Management













GTBP Stock - Frequently Asked Questions

Should I buy or sell GT Biopharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GTBP shares.
View GTBP analyst ratings
or view top-rated stocks.

What is GT Biopharma's stock price forecast for 2023?

2 analysts have issued 12 month price objectives for GT Biopharma's stock. Their GTBP share price forecasts range from $5.00 to $18.00. On average, they predict the company's share price to reach $11.50 in the next twelve months. This suggests a possible upside of 576.5% from the stock's current price.
View analysts price targets for GTBP
or view top-rated stocks among Wall Street analysts.

How have GTBP shares performed in 2022?

GT Biopharma's stock was trading at $3.05 at the start of the year. Since then, GTBP shares have decreased by 44.3% and is now trading at $1.70.
View the best growth stocks for 2022 here
.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (OTCMKTS:GTBP) posted its quarterly earnings data on Monday, October, 31st. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.11.

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), American Cannabis (AMMJ) and GW Pharmaceuticals (GWPH).

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

Who are GT Biopharma's major shareholders?

GT Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.14%), State Street Corp (0.32%), Jane Street Group LLC (0.10%) and Virtu Financial LLC (0.08%).
View institutional ownership trends
.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $1.70.

How much money does GT Biopharma make?

GT Biopharma (OTCMKTS:GTBP) has a market capitalization of $55.35 million. The company earns $-58,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The official website for the company is www.gtbiopharma.com. The company can be reached via phone at (800) 304-9888 or via email at info@oxis.com.

This page (OTCMKTS:GTBP) was last updated on 11/29/2022 by MarketBeat.com Staff